Naproxen in Prophylaxis of Migraine
- 1 June 1985
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 42 (6) , 582-584
- https://doi.org/10.1001/archneur.1985.04060060084014
Abstract
• Naproxen sodium is an inhibitor of platelet aggregation and prostaglandin synthesis and is also a potent anti-inflammatory agent. Because of these properties, it was evaluated in prophylaxis of migraine by a double-blind, placebo-controlled crossover study in 34 patients. Drug "preference" and therapeutic effect were rated by both patient and investigator. Overall, both preferred drug over placebo. An index of migraine activity was calculated from a daily record kept by the patient; it demonstrated a significant reduction in headache severity, duration, disability, and medication needed. Adverse effects were minimal and similar in drug and placebo. Naproxen is a promising agent in the prophylaxis of migraine.This publication has 13 references indexed in Scilit:
- PLATELET NUCLEOTIDES IN MIGRAINEThe Lancet, 1982
- MIGRAINE: A PLATELET DISORDERThe Lancet, 1981
- Naproxen in the Prevention of Migraine Attacks. A Double‐blind Placebo‐controlled Cross‐over StudyHeadache: The Journal of Head and Face Pain, 1980
- TOLFENAMIC ACID IS AS EFFECTIVE AS ERGOTAMINE DURING MIGRAINE ATTACKSThe Lancet, 1979
- ASPIRIN PROPHYLAXIS IN MIGRAINEThe Lancet, 1978
- Platelet aggregability in migraineNeurology, 1977
- Cyclic Changes in Platelet Dynamics and the Pathogenesis and Prophylaxis of MigraineHeadache: The Journal of Head and Face Pain, 1977
- Ophthalmoplegic Migraine: Amelioration by Flufenamic acid, a Prostaglandin inhibitorOphthalmologica, 1977
- “COMPLICATED MIGRAINE” ITS ASSOCIATION WITH INCREASED PLATELET AGGREGABILITY AND ABNORMAL PLASMA COAGULATION FACTORSHeadache: The Journal of Head and Face Pain, 1975
- 5-Hydroxytryptamine levels and platelet aggregation responses in subjects with acute migraine headacheJournal of Neurology, Neurosurgery & Psychiatry, 1972